Opportunity Assessment Of Periodic Fever Syndrome Market Reveals Lucrative Prospects For Manufacturers

19/feb/2020 12:25:01 persistencemarketresearch Contatta l'autore

Questo comunicato è stato pubblicato più di 3 mesi fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Despite similarities in symptoms, periodic fever syndrome has different patterns of inheritance, causes, length and frequency of 'attacks.' Some of the chronic condition associated with Periodic Fever Syndrome includes Cryopyrin-associated periodic syndrome (CAPS), hyperimmunoglobulinemia D syndrome (HIDS), TNF receptor-associated periodic syndrome (TRAPS) and Periodic Fever, Aphthous Stomatitis, Pharyngitis, Adenitis Syndrome (PFAPA) .

The symptoms of Periodic Fever Syndrome are cyclic in nature, coming and going, with the difference in severity.

Periodic Fever Syndrome affects many organs and tissues and has its own set of symptoms along with high temperature during attacks. Elevated serum levels of acute-phase reactants such as fibrinogen and serum amyloid A, leukocytosis and high level of erythrocyte sedimentation rate (ESR) are associated with periodic fever syndrome.

To Remain ‘Ahead’ Of Your Competitors, Request for a Sample Here @ https://www.persistencemarketresearch.com/samples/12190 

Diagnostic tools and genetic test are available for patients with periodic fever. For some conditions such as Periodic Fever, Aphthous Stomatitis, Pharyngitis, Adenitis Syndrome (PFAPA), no genetic test are available yet. Hereditary periodic fever syndromes (HPFSs) are rare and is characterized by short and recurrent attacks.

These attacks undergo remission without the use of antibiotic, anti-inflammatory, or immunosuppressive treatment. The patient feels healthy and is back to its daily routine until the next episode of periodic fever occurs.

Previously, there was no approved medicine for the treatment of TNF Receptor-Associated Periodic Syndrome (TRAPS), Hyperimmunoglobulinemia D Syndrome (HIDS)/ Mevalonate Kinase Deficiency (MKD). In September 2016, the US Food and Drug Administration (FDA) has granted Novartis’ ilaris (canakinumab) expanded use for the treatment of these three rare and distinct types of Periodic Fever Syndromes.

Treatment with oral anti-inflammatory drugs, e.g. corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs), helps to control the symptoms but does not assist in the prevention of Periodic Fever Syndrome.

The global periodic fever syndrome is segmented on the basis of indication, treatment, end user, and geography:

Segmentation by Indication

  • Hyperimmunoglobulinemia D Syndrome (HIDS)
  • Familial Mediterranean Fever (FMF)
  • TNF Receptor-Associated Periodic Syndrome (TRAPS)
  • Cryopyrin-Associated Periodic Syndrome (CAPS)
  • Others

Segmentation by Treatment

  • Oral anti-inflammatory drugs (corticosteroid)
  • Non-steroidal anti-inflammatory drugs (NSAIDs)
  • Anti-TNF therapy
  • Statins
  • Others

Segmentation by End User

  • Hospitals
  • Retail pharmacy

Access Full TOC of This Report @ https://www.persistencemarketresearch.com/toc/12190  

blog comments powered by Disqus
Comunicati.net è un servizio offerto da Factotum Srl